In CKD, Gabapentin Effective for Pruritus, RLS
the MPR take:
Can gabapentin relieve two common symptoms associated with chronic kidney disease (CKD) and end-stage kidney disease (ESKD)? An article published in the Journal of Pain and Symptom Management discusses the use of gabapentin to treat uremic pruritus and restless leg syndrome (RLS) in patients with CKD and ESKD. In this study, 44% of conservatively managed patients with CKD and ESKD complained of pruritus, RLS or both. The median daily dose of gabapentin used in the study was 100mg/day. Gabapentin was shown to be a viable treatment for these patients; it reduced symptoms of RLS (P<0.05) and pruritus (P<0.001), with improvement in symptoms continuing for 83% of patients. Gabapentin treatment was associated with side effects (eg, drowsiness, dizziness, fatigue); 47% of patients experienced side effects while 17% discontinued treatment because of them. More studies will need to be conducted to determine optimum dosing to balance symptom control and side effects.
Pruritus and restless legs syndrome (RLS) frequently affect patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD), impacting quality of life. Gabapentin alleviates these symptoms in hemodialysis (HD) patients but data are lacking for patients on the conservative pathway.